Researchers at the University of Georgia have developed a promising universal flu vaccine using nanoparticles, with highly encouraging results from mouse trials.
Flu epidemics claim hundreds of thousands of lives worldwide each year. In 2018, Bill Gates pledged millions to accelerate vaccine research. A standout candidate emerged from the University of Georgia: a nanoparticle-based vaccine announced on January 6, 2020. It successfully protected mice against six different flu virus strains, demonstrating broad potential.
The vaccine combines antigens in nanoparticles for robust, cross-strain protection—the key to a true universal flu shot that eliminates the need for annual updates. It centers on the neuraminidase (NA) protein displayed on an M2e protein core. Unlike the rapidly mutating hemagglutinin (HA) protein used in other studies, NA evolves more slowly, making it ideal for long-lasting immunity.
While proven effective in mice, human trials are the next step. This innovation could transform flu prevention.
Related Articles:
